{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:41Z","timestamp":1787019641399,"version":"build-2736575974"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mediastinal gray zone lymphoma (MGZL) is defined in the international World Health Organization classification as a B-cell lymphoma with overlapping clinical, morphological, immunophenotypic, and molecular features between primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (CHL), particularly nodular sclerosis CHL (NSCHL). Recent molecular studies have highlighted the similarities between these 3 entities, relying on immune escape, JAK-STAT, and nuclear factor-\u03baB pathway alterations without specific features related to MGZL. These studies shed light on the different pathobiology of extramediastinal cases, leading to the conclusion that these cases are generally better classified as diffuse large B-cell lymphoma (DLBCL)-not otherwise specified. The absence of Epstein-Barr virus (EBV) on the biopsy is also a desirable criterion, leading to the differential diagnosis of EBV-positive DLBCL. Most studies reporting clinical and treatment data suggest that more intensive induction regimens provide greater disease control compared to standard regimens. Given the paucity of dedicated clinical trials, it remains unknown if, and when, the evolving therapeutic options of PMBL and NSCHL will become available to those with MGZL, offering novel immune-based treatments to these patients with a higher risk of primary chemorefractory disease.<\/jats:p>","DOI":"10.1182\/hematology.2025000748c","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:09:48Z","timestamp":1764943788000},"page":"547-554","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"first","affiliation":[{"name":"1 Institut Curie, Department of Hematology, U1288 Universit\u00e9 Versailles Saint-Quentin-en-Yveline, Saint Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Traverse-Glehen","sequence":"additional","affiliation":[{"name":"2 Hospices Civils de Lyon, Department of Pathology, Universit\u00e9 Lyon 1, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"20","key":"2025120616344920600_hem2025000748CC1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2025120616344920600_hem2025000748CC2","article-title":"Mediastinal grey zone lymphoma","volume-title":"Haematolymphoid Tumours","author":"Sarkozy","year":"2024","edition":"5"},{"issue":"12","key":"2025120616344920600_hem2025000748CC3","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2025120616344920600_hem2025000748CC4","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2025120616344920600_hem2025000748CC5","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"issue":"suppl 5","key":"2025120616344920600_hem2025000748CC6","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/annonc\/9.suppl_5.S31","article-title":"Workshop report on Hodgkin's disease and related diseases (\u201cgrey zone\u201d lymphoma)","volume":"9","author":"Rudiger","year":"1998","journal-title":"Ann Oncol"},{"issue":"11","key":"2025120616344920600_hem2025000748CC7","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/01.pas.0000180856.74572.73","article-title":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma","volume":"29","author":"Traverse-Glehen","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2025120616344920600_hem2025000748CC8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2559.2005.02175.x","article-title":"Large B-cell lymphoma with Hodgkin's features","volume":"47","author":"Garcia","year":"2005","journal-title":"Histopathology"},{"issue":"4","key":"2025120616344920600_hem2025000748CC9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12308-009-0053-9","article-title":"Gray zones around diffuse large B cell lymphoma: conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France","volume":"2","author":"Quintanilla-Martinez","year":"2009","journal-title":"J Hematop"},{"issue":"2","key":"2025120616344920600_hem2025000748CC10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3960\/jslrt.50.143","article-title":"Two cases of mediastinal gray zone lymphoma","volume":"50","author":"Minami","year":"2010","journal-title":"J Clin Exp Hematop"},{"issue":"7","key":"2025120616344920600_hem2025000748CC11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2025120616344920600_hem2025000748CC12","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2011.116","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations","volume":"24","author":"Eberle","year":"2011","journal-title":"Mod Pathol"},{"issue":"13","key":"2025120616344920600_hem2025000748CC13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.2020007507","article-title":"Mutational landscape of grey zone lymphoma","volume":"137","author":"Sarkozy","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2025120616344920600_hem2025000748CC14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/2643-3230.BCD-20-0009","article-title":"Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma","volume":"1","author":"Pittaluga","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2025120616344920600_hem2025000748CC15","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020001923","article-title":"Gene expression profiling of gray zone lymphoma","volume":"4","author":"Sarkozy","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2025120616344920600_hem2025000748CC16","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2018-05-851154","article-title":"Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens","volume":"132","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2025120616344920600_hem2025000748CC17","first-page":"3771","article-title":"A targeted gene signature stratifying mediastinal gray zone lymphoma into classical Hodgkin lymphoma-like or primary mediastinal B-cell lymphoma-like subtypes","volume":"109","author":"Gargano","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"2025120616344920600_hem2025000748CC18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2025120616344920600_hem2025000748CC19","doi-asserted-by":"crossref","first-page":"115369","DOI":"10.1016\/j.ejca.2025.115369","article-title":"Primary mediastinal B-cell lymphoma (PMBCL): the LYSA pragmatic guidelines","volume":"220","author":"Renaud","year":"2025","journal-title":"Eur J Cancer"},{"key":"2025120616344920600_hem2025000748CC20","doi-asserted-by":"crossref","first-page":"115073","DOI":"10.1016\/j.ejca.2024.115073","article-title":"Classic Hodgkin lymphoma: the LYSA pragmatic guidelines","volume":"213","author":"Rossi","year":"2024","journal-title":"Eur J Cancer"},{"issue":"10450","key":"2025120616344920600_hem2025000748CC21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"2025120616344920600_hem2025000748CC22","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120616344920600_hem2025000748CC23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"2025120616344920600_hem2025000748CC24","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2014-03-564906","article-title":"A prospective study of mediastinal gray-zone lymphoma","volume":"124","author":"Wilson","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025120616344920600_hem2025000748CC25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2016.152256","article-title":"Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association","volume":"102","author":"Sarkozy","year":"2017","journal-title":"Haematologica"},{"issue":"26","key":"2025120616344920600_hem2025000748CC26","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/bloodadvances.2017009472","article-title":"Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL","volume":"1","author":"Pilichowska","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2025120616344920600_hem2025000748CC27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.14226","article-title":"Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma","volume":"179","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"9806","key":"2025120616344920600_hem2025000748CC28","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"R\u00e9cher","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"2025120616344920600_hem2025000748CC29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3324\/haematol.2023.283446","article-title":"Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients","volume":"109","author":"Cook","year":"2024","journal-title":"Haematologica"},{"issue":"15","key":"2025120616344920600_hem2025000748CC30","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"2025120616344920600_hem2025000748CC31","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","article-title":"Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study","volume":"5","author":"Camus","year":"2021","journal-title":"Blood Adv"},{"issue":"34","key":"2025120616344920600_hem2025000748CC32","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO-24-01373","article-title":"Omission of radiotherapy in primary mediastinal B-Cell lymphoma: IELSG37 trial results","volume":"42","author":"Martelli","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025120616344920600_hem2025000748CC33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.16331","article-title":"Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma\/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases","volume":"189","author":"Aussedat","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"2025120616344920600_hem2025000748CC34","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2014-03-564906","article-title":"A prospective study of mediastinal gray-zone lymphoma","volume":"124","author":"Wilson","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025120616344920600_hem2025000748CC35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc1704767","article-title":"PD-1 blockade in mediastinal gray-zone lymphoma","volume":"377","author":"Melani","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2025120616344920600_hem2025000748CC36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00277-017-3179-3","article-title":"Favorable response of relapsed\/ refractory gray-zone lymphoma to brentuximab vedotin","volume":"97","author":"Li","year":"2018","journal-title":"Ann Hematol"},{"issue":"22","key":"2025120616344920600_hem2025000748CC37","first-page":"2780","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory mediastinal gray zone lymphoma","volume":"141","author":"Santoro","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2025120616344920600_hem2025000748CC38","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025120616344920600_hem2025000748CC39","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41375-024-02213-x","article-title":"Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study","volume":"38","author":"Chiappella","year":"2024","journal-title":"Leukemia"},{"issue":"13","key":"2025120616344920600_hem2025000748CC40","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1080\/10428194.2022.2107204","article-title":"Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory\/relapsed Hodgkin lymphoma: a lymphoma study association phase I\/ II study","volume":"63","author":"Stamatoullas","year":"2022","journal-title":"Leuk Lymphoma"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/547\/2470011\/547sarkozy.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/547\/2470011\/547sarkozy.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:34:55Z","timestamp":1765056895000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/547\/556846\/All-shades-of-gray-in-the-mediastinum-do-we-have"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000748c","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}